PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis
NCT06511037
Recruiting
This is a pilot, single-arm, open label study to evaluate the ability of CYTALUX™ (pafolacianine) to help identify cancerous lesions in subjects with gastrointestinal cancers and peritoneal carcinomatosis during cytoreductive surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California
Conditions: Gastrointestinal Cancer, Peritoneal Carcinomatosis
Register for Updates
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
NCT06643481
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of ALS symptoms onset). The study comprises a core double-blind (DB) 40-week treatment period followed by an open label extension (OLE).
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/06/2025
Locations: Nerve and Muscle Center of Texas, Houston, Texas
Conditions: Amyotrophic Lateral Sclerosis (ALS)
Register for Updates
Two Dose Levels of Privigen in Pediatric CIDP
NCT03684018
Recruiting
A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
02/06/2025
Locations: Phoenix Children's Hospital, Phoenix, Arizona +8 locations
Conditions: Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Register for Updates
EyeConic: Qualification for Cone-Optogenetics
NCT05294978
Recruiting
This study aims to prepare for the first-in-human clinical trial of cone optogenetics vision restoration. As a first step, this worldwide multicenter ocular imaging study (EyeConic Study) is performed to identify eligible patients.
Gender:
ALL
Ages:
All
Trial Updated:
02/06/2025
Locations: University of California San Francisco, Department of Ophthalmology, San Francisco, California +8 locations
Conditions: Retinal Dystrophies
Register for Updates
Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
NCT05633979
Recruiting
To find a recommended dose of valemetostat that can be given in combination with trastuzumab deruxtecan to patients with low/ultra-low HER2-expressing metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)
NCT05892432
Recruiting
This study is a randomized controlled trial of oral semaglutide among treatment-seeking individuals with AUD. The investigators will randomly assign 50 participants to receive semaglutide (titrated to 7 milligrams (mg) per day) or matched placebo for 8 weeks. The primary aims are to assess the safety and tolerability of semaglutide in this population and to evaluate its effects, relative to placebo, on alcohol cue-elicited craving and alcohol consumption.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
02/06/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Alcohol Use Disorder
Register for Updates
Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects
NCT06221800
Recruiting
This is a pilot study collecting data on the diversity and composition of gut microbiomes in subjects with advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) while receiving treatment for NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: Chao Family Comprehensive Cancer Center University of California, Irvine, Orange, California
Conditions: Non Small Cell Lung Cancer
Register for Updates
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
NCT06522386
Recruiting
Primary Objectives: To estimate the percent of participants who achieve a best response of complete response by the end of the PRV combination therapy in the induction therapy phase in patients with previously untreated MCL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Mantle Cell Lymphoma
Register for Updates
Optimizing Low Vision Rehabilitation in Emotionally Distressed Patients With Inherited Retinal Diseases
NCT06651736
Recruiting
The purpose of this study is to understand if combining Low Vision Rehabilitation (LVR) with Emotional Regulation Therapy (ERT) can help people with inherited retinal diseases (IRDs) that experience emotional distress related to participants' vision loss. The study team hypothesize that treatment with LVR will produce measurable functional gains and that these effects will be enhanced by ERT-linked improvement among the subgroup of IRD patients with elevated vision-related anxiety.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Inherited Retinal Diseases
Register for Updates
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
NCT03755804
Recruiting
This is a phase II study using risk and response-adapted therapy for low, intermediate and high risk classical Hodgkin lymphoma. Chemotherapy regimens will be based on risk group assignment. Low-risk and intermediate- risk patients will be treated with bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine, and prednisone (BEABOVP) chemotherapy. High-risk patients will receive Adcetris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxo... Read More
Gender:
ALL
Ages:
25 years and below
Trial Updated:
02/06/2025
Locations: Lucile Packard Children's Hospital Stanford University, Palo Alto, California +7 locations
Conditions: Hodgkin Lymphoma
Register for Updates
A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma
NCT05323253
Recruiting
This is a multi-center clinical study enrolling up to 86 participants. The primary objectives are to determine the objective response rate (ORR) established by the confirmed best overall response (BOR) following intratumoral administration of DaRT - Diffusing Alpha-Emitters Radiation Therapy, as well as to assess the Duration of Response (DOR) 6 months from initial response. Secondary objectives are to assess the safety of DaRT, and to assess the progression free survival (PFS), overall survival... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2025
Locations: Banner Health MD Anderson Phoenix, Gilbert, Arizona +30 locations
Conditions: Recurrent Squamous Cell Carcinoma
Register for Updates
From Nerve to Brain: Toward a Mechanistic Understanding of Spinal Cord Stimulation in Human Subjects
NCT05661903
Recruiting
This is a multicenter prospective study of patients who currently have stably implanted spinal cord simulators. Patients will be randomly assigned to turn on or off their spinal cord stimulators for two week intervals up to six weeks after enrollment, and on the final day of study participation, for one hour intervals, in a multi-crossover design. In a subset of patients we will also perform combined positron emission tomography/magnetic resonance imaging at baseline, week 2 and week 4.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/06/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Chronic Pain
Register for Updates